Background
==========

Lipodystrophies are a heterogeneous group of diseases that result in abnormal fat distribution and severe insulin resistance \[[@B1]-[@B5]\]. The molecular basis for several forms of partial and complete lipodystrophy syndromes have been characterized \[[@B6]\], but some patients with inherited lipodystrophies do not have mutations in the known lipodystrophy genes. Finding other candidate genes for evaluation can be challenging because the families of such probands are often small, so positional cloning (or linkage analysis) using genome-wide marker sets cannot be performed. Another approach to find causative mutations is to select human candidate genes by analogy from genes that have been manipulated in animal models with a comparable phenotype. For instance, mice with induced deficiency in *Cav1*encoding the cell surface protein caveolin-1 (MIM 601047) showed depleted and abnormal adipocytes with insulin resistance and severe hypertriglyceridemia \[[@B7]-[@B9]\]. Since no human mutations in *CAV1*have yet been reported, we screened the genomic DNA of 60 unrelated adults with partial lipodystrophy and hypertriglyceridemia and no mutation in any known lipodystrophy gene to search for coding sequence mutations in *CAV1*.

Results
=======

Demographics of study sample
----------------------------

From a tertiary referral lipid clinic, we evaluated 60 patients (80% female) who had partial lipodystrophy, with diabetes or moderate to severe (type 4 or 5) hypertriglyceridemia. Age, body mass index, untreated fasting plasma cholesterol and triglycerides (mean+standard deviation \[SD\]) were, respectively, 52.5 ± 14.0 years, 26.2 ± 3.8 kg/m^2^, 6.9 ± 5.0 mmol/L and 11.1+10.0 mmol/L. All subjects consented to DNA analysis. No coding sequence mutations were found in *LMNA*, *PPARG*, *BSCL2*or *AGPAT2*genes encoding nuclear lamin A/C, peroxisome proliferator-activated receptor gamma, seipin or 1-acyl-sn-glycerol-3-phosphate acetyltransferase, respectively.

Characterization of patients with *CAV1*mutations
-------------------------------------------------

Two rare heterozygous coding sequence variants in *CAV1*were found among the screened patients, I134fsdelA-X137 in one patient and -88delC in another (Figure [1](#F1){ref-type="fig"}). These frameshift mutations were absent from the genomes of 1063 normolipidemic control subjects. The I134fsdelA-X137 mutation predicted premature termination, with loss of the carboxy terminal half of the protein product. This mutation was subsequently found in the proband\'s father, who had a similar phenotype. The -88delC mutation occurred within the 5\'-untranslated region with a potential effect on the reading frame. The clinical features of the father and daughter with the heterozygous I134fsdelA-X137 mutation and the singleton patient with the heterozygous -88delC mutation are summarized in Table [1](#T1){ref-type="table"}.

###### 

Clinical and biochemical features of atypical lipodystrophy patients with *CAV1*mutations

  **Attribute**                            **Patient A**                                                                 **Patient B**                        **Patient C**
  ---------------------------------------- ----------------------------------------------------------------------------- ------------------------------------ ---------------------------------
  Ancestry                                 Northern Europe                                                               Northern Europe                      Northern Europe
  *CAV1*mutation name                      I134fsdelA-X137                                                               I134fsdelA-X137                      -88delC
  age at assessment (years)                28                                                                            55                                   35
  sex                                      female                                                                        male                                 male
  lipodystrophy onset                      birth                                                                         birth                                adulthood
  BMI (kg/m^2^)                            25.0                                                                          24.5                                 25.6
  waist circumference (cm)                 86                                                                            88                                   92
  Subcutaneous fat changes:                                                                                                                                   
   face                                    decrease                                                                      decrease                             increase
   arms                                    decrease                                                                      decrease                             decrease
   gluteal region                          increase                                                                      increase                             decrease
   thighs                                  increase                                                                      increase                             decrease
   calves                                  increase                                                                      increase                             decrease
   visceral                                increase                                                                      increase                             increase
                                                                                                                                                              
  age of diabetes onset (years)            none                                                                          30                                   33
  hypertension and age of onset            none                                                                          none                                 33
  hyperlipoproteinemia                     type 5                                                                        type 4                               type 5
  pancreatitis                             recurrent                                                                     no                                   recurrent
  highest historical plasma triglyceride   20.4 mmol/L                                                                   80 mmol/L                            16.5 mmol/L
  acanthosis nigricans                     present                                                                       absent                               present
                                                                                                                                                              
  congenital cataracts                     bilateral                                                                     bilateral                            absent
  atypical retinitis pigmentosa            bilateral                                                                     bilateral                            absent
                                                                                                                                                              
  tinnitus                                 moderate                                                                      absent                               absent
                                                                                                                                                              
  nystagmus                                severe                                                                        absent                               absent
  spastic ataxia                           severe                                                                        mild                                 absent
  dysdiadochokinesia                       severe                                                                        mild                                 absent
  muscle power in lower limbs              diminished (4/5)                                                              normal                               normal
  sensory glove/stocking neuropathy        severe                                                                        mild                                 absent
  Babinski sign                            bilateral                                                                     absent                               absent
  finger past-pointing                     severe                                                                        absent                               absent
                                                                                                                                                              
  other comments                           wheel-chair bound since age 20; similarly affected paternal aunt (deceased)   Patient A\'s father; legally blind   requires 120 U of insulin daily

![Electropherogram scans showing the novel heterozygous *CAV1*frameshift mutations in the lipodystrophy patients. The left half of the figure shows a portion of *CAV1*exon 2 from genomic DNA of a control subject and Patient A. The right half of the figure shows a portion of *CAV1*5\' untranslated region (5\'UTR) from genomic DNA of a control subject and Patient C. For each tracing, normal nucleotide sequence is shown in the top line of letters, with single letter amino acid codes and codon numbers beneath for exon sequence. The position of each inserted nucleotide is indicated by the arrows for the respective mutations I134fsdelA-X137 and -88delC.](1476-511X-7-3-1){#F1}

The history and clinical features of the I134fsdelA-X137 mutation proband (Patient A) and her affected father (Patient B) have been previously reported \[[@B10]\]. Briefly, the proband, who was assessed at age 28 years, was a woman of Northern European origin who was wheelchair bound since early adulthood. At birth, she was noted to have a lack of facial and upper body subcutaneous fat, micrognathia and congenital cataracts. Later, diplopia, tinnitus and a central auditory processing defect were noted. She had severe type 5 hyperlipoproteinemia with recurrent pancreatitis; she had insulin resistance but no diabetes. On examination, she was noted to have orthostatic hypotension, a high arched palate, taut skin with sparing of subcutaneous fat on buttocks, hips and thighs. She was noted also to have webbed toes, acanthosis nigricans, retinitis pigmentosa, iris deposits, marked nystagmus, ocular dysmetria, past-pointing on finger-nose testing, dysdiadochokinesis, a spastic-ataxic gait, spontaneous clonus of legs, bilateral Babinski signs, reduced power in the lower extremity and lost vibration sense in a glove-and-stocking distribution. She had leg spasms, a stiff gait, paresthesiae, imbalance and urinary incontinence. Investigations showed lipemic plasma with markedly elevated serum cholesterol (9.3 mmol/L) and triglycerides (20.4 mmol/L). Her father (Patient B), a 55 year old diabetic man of Northern European origin, had similar body fat distribution to his daughter. He also had congenital cataracts and retinitis pigmentosa, but no neurological complaints, and was ambulatory and well-functioning. On examination, he was noted to have absent facial, neck, and limb fat with increased abdominal and lower back subcutaneous fat. He also had decreased sensation in both legs, with normal muscle power and tone; an unsteady narrow-based gait was elicited. He had milder biochemical abnormalities than his daughter, with mild hypertriglyceridemia and no history of pancreatitis. Of note, Patient B\'s sister (the paternal aunt of Patient A) died from an undefined neurological condition at age 40. Medical records showed a clinical presentation similar to Patient A, with analogous fat redistribution, leg weakness and ataxia beginning at age 18 and requirement for a wheelchair at age 20 \[[@B10]\]. Patient C, a heterozygote for the *CAV1*-88delC mutation, was 35 years old at assessment. He was noted in his early 20\'s to have redistributed fat stores, with a relative loss of subcutaneous fat on his arms, gluteal region, thighs and calves and increased visceral fat on abdominal ultrasound examination. He had severe hypertriglyceridemia (range 10 to 80 mmol/L) beginning in his late 20\'s, with recurrent episodes of pancreatitis. He was diagnosed with diabetes at age 33 and currently takes 120 units of insulin daily in addition to fenofibrate 200 mg daily. Physical examination revealed fat redistribution, with no ocular, neurological, dermatologic or musculoskeletal findings.

Discussion
==========

Caveolin-1 is expressed in numerous tissues and is a central component of cell surface caveoli, which are plasma membrane microdomains that regulate signaling pathways and processes such as cell migration, polarization, proliferation and especially endocytosis \[[@B11]-[@B13]\]. *Cav1*appears to have a significant role in murine adipocyte metabolism, and disruption of the gene leads to severe hypertriglyceridemia, insulin resistance and adipocyte abnormalities, which are all features that are consistent with human partial lipodystrophy \[[@B7]-[@B9]\]. Our genetic findings suggest that *CAV1*might also have a role in human adipose, insulin and triglyceride metabolism, albeit only two frameshift mutations in *CAV1*were found among 60 lipodystrophic patients with a normal coding sequence of known lipodystrophy genes.

The frameshift mutations would be expected to result in a compromised gene product from the affected allele. The I134fsdelA-X137 mutation co-segregated with the phenotype from father to daughter, but the more severe phenotype in the daughter suggests that other factors -- perhaps genetic or non-genetic -- can modulate the severity of the phenotype. The presence of a comparably severe phenotype in Patient A\'s paternal aunt suggests that gender might also modulate the severity of phenotypic expression in carriers. Also, the variable organ system involvement -- the ocular and central nervous systems in Patients A and B but not in Patient C -- is consistent with the variable multi-system phenotypes seen in *Cav1*deficient mice depending on genetic background \[[@B11]-[@B13]\]. However, heterozygous *Cav1*deficient mice do not show any phenotype, again suggesting that other factors are required for phenotypic expression in these patients. Unfortunately, we could not further extend the families in order to document phenotypes seen in other *CAV1*mutation carriers at present, although this is planned for the future.

Conclusion
==========

The association of these rare frameshift mutations in *CAV1*with atypical presentations of partial lipodystrophy with insulin resistance and hypertriglyceridemia, the absence of these mutations from healthy controls together with evidence from mouse models link the *CAV1*gene with human metabolic phenotypes. Since only two mutations were found among 60 screened subjects, *CAV1*mutations are a very rare cause of lipodystrophy and hypertriglyceridemia.

Methods
=======

Genomic DNA analysis
--------------------

The exons and intron-exon boundaries of *CAV1*were amplified and bi-directionally sequenced using the primers and conditions in Table [2](#T2){ref-type="table"}. All coding sequence mutations were confirmed by a second sequencing reaction performed on another day. The frequency of the *CAV1*exon 3 I134fsdelA-X137 variant was determined in healthy control subjects using genomic DNA amplification with primers 5\'-ATG GAT ACT GAA TAG TGG GTT TTT and 5\'-TGT TGC TGT ATT AGC AAC TTG GA. The 509 bp product was digested with restriction enzyme *Nsi*I (New England Biolabs, Mississauga, ON) and fragments were resolved on 2% agarose gels. The digested fragments of the wild-type allele were 280 and 229 base pairs (bp) in size, while the digested fragment of the mutant allele was 509 bp in size. The frequency of the *CAV1*exon 1 -88delC variant was determined in healthy control subjects using genomic DNA amplification with primers 5\'-AG ATG ATG CAC TGG GAA AA and 5\'-CTA GGC CCC CTC TCC ATT AG, with allele specific diagnostic (SNaPShot) primer 5\'-GAT CTT GTA TTG TAT GGG GG.

###### 

Primers used for sequencing *CAV1*

  ---------------------------------------------------------------------------------------
  Exon   Primers                                  Fragment size (nucleotide base pairs)
  ------ ---------------------------------------- ---------------------------------------
  1      F-5\' GAG ATG ATG CAC TGG GAA AA\        633
         R-5\' CTA GGC CCC CTC TCC ATT AG         

  2      F-5\' GTA GCT GTC GGA GCG GTT AG\        480
         R-5\' GGA GCT CCC ACA CAT CAA AC         

  3      F-5\' ATG GAT ACT GAA TAG TGG GTT TTT\   509
         R-5\' TGT TGC TGT ATT AGC AAC TTG GA     
  ---------------------------------------------------------------------------------------
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